SCHEMBL5134952

SCHEMBL5134952

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(C)cc1)Cc1ccc(OC)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.44
KDM4E B2RXH2 5/20 0.43
LMNA P02545 4/20 0.43
HTT P42858 3/20 0.43
ALDH1A1 P00352 6/20 0.41
TSHR P16473 4/20 0.41
GAA P10253 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
HSD17B10 Q99714 2/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
TP53 P04637 2/20 0.39
MAPT P10636 2/20 0.39
BCHE P06276 3/20 0.39
CNR2 P34972 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PDE4B Q07343 1/20 0.38
HPGD P15428 2/20 0.38
NPC1 O15118 1/20 0.38
POLB P06746 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL651365 0.97 C5AR1 (0.46) C5AR1KDM4ELMNAHTTALDH1A1
SCHEMBL5072205 0.96 C5AR1 (0.46) C5AR1KDM4ELMNAHTTALDH1A1
SCHEMBL5136291 0.95 C5AR1 (0.45) C5AR1KDM4ELMNAHTTALDH1A1
SCHEMBL5136763 0.94 KDM4E (0.43) C5AR1KDM4ELMNAHTTALDH1A1
SCHEMBL5136185 0.94 C5AR1 (0.44) C5AR1KDM4ELMNAHTTALDH1A1
SCHEMBL5135582 0.93 ATP4A (0.44) C5AR1KDM4ELMNAALDH1A1TSHR
SCHEMBL5135687 0.93 C5AR1 (0.45) C5AR1KDM4ELMNAHTTALDH1A1
SCHEMBL5137368 0.92 TP53 (0.46) C5AR1KDM4ELMNAHTTALDH1A1
SCHEMBL5137707 0.92 C5AR1 (0.43) C5AR1KDM4ELMNAHTTALDH1A1
SCHEMBL5136799 0.92 C5AR1 (0.43) C5AR1KDM4ELMNAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed